Mapping the MoA Behind GI Protection From Bif195

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

January 12, 2021

Study Completion Date

January 12, 2021

Conditions

Reduction of Small Intestinal Ulceration Risk

Interventions

DIETARY_SUPPLEMENT

Bif195

Active trial product with minimum 100 billion CFU daily dose

OTHER

Placebo

Placebo similar to trial product but without Bif195

Trial Locations (1)

Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup

All Listed Sponsors

lead

Chr Hansen

INDUSTRY

NCT04448847 - Mapping the MoA Behind GI Protection From Bif195 | Biotech Hunter | Biotech Hunter